Future Virol
Future Virol
Country: Unknown
Publisher: Unknown
Publication Period: Unknown
43
Papers in Database
Journal Information
Publication Details
Additional Information
Subject Term Count: 1
Last Updated: Aug 05, 2025
Recent Papers
View All 43 PapersAntiviral attributes of bee venom as a possible therapeutic approach against SARS-CoV-2 infection.
Goswami S, Chowdhury JP.
CpG 684: an effective adjuvant for the inactivated COVID-19 vaccine in mice.
Liu J, Cang T, Jiang C, Li K, Liu S, Wang H, Wang M, Chen Y, Shao Y, Liu J.
DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes.
Nag S, Mandal S, Mukherjee O, Mukherjee S, Kundu R.
Natural killer cells in COVID-19: from infection, to vaccination and therapy.
Zafarani A, Razizadeh MH, Pashangzadeh S, Amirzargar MR, Taghavi-Farahabadi M, Mahmoudi M.
Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY).
Horga A, Saenz R, Yilmaz G, Simón-Campos A, Pietropaolo K, Stubbings WJ, Collinson N, Ishak L, Zrin…
Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19.
Horga A, Kuritzkes DR, Kowalczyk JJ, Pietropaolo K, Belanger B, Lin K, Perkins K, Hammond J.
Structure-based virtual identification of natural inhibitors of SARS-CoV-2 and its Delta and Omicron variant proteins.
Alanzi AR, Parvez MK, Al-Dosari MS.
Targeting host calcium channels and viroporins: a promising strategy for SARS-CoV-2 therapy.
Fani M, Moossavi M, Bakhshi H, Jahrodi AN, Khazdair MR, Zardast AH, Ghafari S.
Validation of a risk prediction model for COVID-19: the PERIL prospective cohort study.
Mohammedain SA, Badran S, Elzouki AY, Salim H, Chalaby A, Siddiqui M, Hussein YY, Rahim HA, Thalib …
A comprehensive account of SARS-CoV-2 genome structure, incurred mutations, lineages and COVID-19 vaccination program.
Rajpal VR, Sharma S, Sehgal D, Singh A, Kumar A, Vaishnavi S, Tiwari M, Bhalla H, Goel S, Raina SN.